title: A less intensive combination of paclitaxel and carboplatin in advanced non-small cell lung cancer patients who have aged 60 years or more and has a poor performance status.
abstract: BACKGROUND
  The aim of this study was to evaluate the response, survival, and toxicities of a less intensive combination of paclitaxel and carboplatin, which is used in advanced non-small cell lung cancer (NSCLC) patients older than 60 years of age including those with a poor performance status.
  
  
  METHODS
  Thirty patients received 135 mg/m2 of paclitaxel on day 1, and carboplatin was administered to the patients on day 1 every 4 weeks over an area under the concentration-time curve of 6.
  
  
  RESULTS
  The response rate was 40%, the median overall survival was 9.1 months (95% CI, 4.2 to 14 months), and the 1 year survival rate was 31%. The median progression-free survival was 7.7 months (95% CI, 3.1 to 12.2 months). In addition, the toxicities were generally mild and reversible.
  
  
  CONCLUSIONS
  This study demonstrates that a less intensive combination of paclitaxel/carboplatin is active and well tolerated in advanced NSCLC patients who are older than 60 years including those with a poor PS 3-4.
authors.affiliation: Department of Internal Medicine, Radiation Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
authors.forename: Young Joo
authors.initials: YJ
authors.lastname: Min
authors.forename: Jong Joon
authors.initials: JJ
authors.lastname: Ahn
authors.forename: Young Ju
authors.initials: YJ
authors.lastname: Noh
authors.forename: Hee Jeong
authors.initials: HJ
authors.lastname: Cha
authors.forename: Jae Hee
authors.initials: JH
authors.lastname: Suh
authors.forename: Jong Pil
authors.initials: JP
authors.lastname: Jung
authors.forename: Chang Ryul
authors.initials: CR
authors.lastname: Park
authors.forename: Ae Kyung
authors.initials: AK
authors.lastname: Jeong
authors.forename: Jae Hoo
authors.initials: JH
authors.lastname: Park
authors.forename: Ki Man
authors.initials: KM
authors.lastname: Lee
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D018434:Sickness Impact Profile; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D016190:Carboplatin; D017239:Paclitaxel